GlassScriptPhysician profile
Abinash Joshi
NPI 1235591983
$6,004.58
in general payments reported to CMS, 2019-2025
32 companies · $1,407 in 2025
The $1,407 reported for 2025 was more than what 77% of Sleep Medicine (Family Medicine) providers received nationally (typical 2025 total: $557).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $54.01 · 2020: $12.17 · 2021: $745 · 2022: $1,025 · 2023: $1,358 · 2024: $1,404 · 2025: $1,407.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,943 · Education: $226.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,942.89 |
| Education | $225.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,010.31 | 2021-2025 | Fasenra, Breztri, Tezspire |
| Actelion Pharmaceuticals US, INC. | $619.83 | 2021-2025 | Uptravi, Opsumit |
| Glaxosmithkline, LLC. | $536.81 | 2021-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Harmony Biosciences LLC | $512.41 | 2021-2025 | Wakix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $404.12 | 2021-2025 | Ofev, Stiolto Respimat, Spiriva Respimat |
| Jazz Pharmaceuticals INC. | $341.34 | 2022-2025 | |
| Inspire Medical Systems, INC. | $261.01 | 2024-2025 | Inspire |
| Philips North America LLC | $233.40 | 2020-2025 | (Ak6) Vest Therapy, (8874) Incourage, Vest Therapy Und |
| Gilead Sciences, INC. | $206.98 | 2022-2024 | Veklury |
| Genzyme Corporation | $202.73 | 2022-2025 | |
| Axsome Therapeutics, INC. | $201.02 | 2022-2024 | Sunosi |
| Mylan Specialty L.P. | $185.93 | 2021-2024 | Yupelri |
| Insmed, INC. | $180.50 | 2023-2024 | Arikayce |
| Regeneron Healthcare Solutions, INC. | $175.56 | 2021-2025 | Dupixent |
| United Therapeutics Corporation | $162.42 | 2022-2025 | Tyvaso, Tyvaso |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $154.91 | 2021-2025 | Prolastin-C Liquid |
| Electromed, INC. | $109.36 | 2022-2025 | Smartvest |
| Amgen INC. | $64.79 | 2022-2025 | Tezspire |
| Teva Pharmaceuticals USA, INC. | $64.38 | 2021-2023 | Cinqair |
| Takeda Pharmaceuticals U.S.A., INC. | $52.15 | 2025 | Glassia, Cuvitru |
| Avadel Cns Pharmaceuticals, LLC | $48.86 | 2024-2025 | Lumryz |
| Csl Behring | $44.68 | 2022 | |
| Novartis Pharmaceuticals Corporation | $41.30 | 2019 | |
| Bard Peripheral Vascular, INC. | $36.95 | 2023-2025 | |
| Viatris Specialty LLC | $31.29 | 2025 | Yupelri |
| Baxter Healthcare | $28.27 | 2023-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Mayne Pharma Commercial LLC | $21.87 | 2021 | |
| Pulmonx Corporation | $17.75 | 2021 | |
| Resmed Corp | $14.15 | 2021 | |
| Merck Sharp & Dohme LLC | $13.45 | 2022 | |
| Genentech USA, INC. | $13.34 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $12.71 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abinash Joshi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.